AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33474858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin provocation
Number of subjects: 92
Study 33474858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization
Number of subjects: 92
Study 33474858 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug provocation
Number of subjects: 92
Study 33474967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 33474976 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hs-cTnT measures below the limit of quantification (LOQ: 6 ng/L)
Number of subjects: 1462
Study 33474976 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk HEART score with initial hs-cTnT below the LOQ
Number of subjects: 1462
Study 33474976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-h algorithm
Number of subjects: 1462
Study 33474976 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-h algorithm with low HEART score
Number of subjects: 1462
Study 33474976 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1462
Study 33475022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical computer-based approach to study AD in real life
Number of subjects: 0
Study 33475231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian dynamic borrowing using a mixture prior combining informative prior from adult data
Number of subjects: 0
Study 33475231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping point analysis
Number of subjects: 0
Study 33475512 — intervention group
Group type: EXPERIMENTAL
Intervention: e-DSI (electronic decision support intervention)
Number of subjects: 60
Study 33475512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility patterns recorded using GPS tracker and travel diary
Number of subjects: 60
Study 33475512 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centered co-design process
Number of subjects: 60
Study 33475512 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangulation and comparison of data from all phases
Number of subjects: 60
Study 33475675 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed sampling of intraoperative parathormone testing (ioPTH)
Number of subjects: 0
Study 33475675 — intervention group
Group type: COMPARATOR
Intervention: Baseline ioPTH
Number of subjects: 0
Study 33475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 50 mg of hyperbaric prilocaine
Number of subjects: 10
Study 33476231 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group preventive intervention
Number of subjects: 0
Study 33476231 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33476252 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Obstructive Pulmonary Disease Knowledge Questionnaire
Number of subjects: 0
Study 33476432 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor treatment, dosage and duration not available
Number of subjects: 0
Study 33476434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, bendamustine, mitoxantrone (R-BM) followed by rituximab consolidation
Number of subjects: 76
Study 33476492 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg every 3 weeks
Number of subjects: 0
Study 33476575 — intervention group
Group type: EXPERIMENTAL
Intervention: IRF4 antisense oligonucleotides (ASOs)
Number of subjects: 0
Study 33476575 — intervention group
Group type: EXPERIMENTAL
Intervention: IRF4 ASOs
Number of subjects: 0
Study 33476658 — intervention group
Group type: EXPERIMENTAL
Intervention: Four approaches to treat actinic keratosis
Number of subjects: 0
Study 33477665 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior related to treatment of LUTS
Number of subjects: 0
Study 33477964 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized human milk fortification using a multi-nutrient fortifier and modular supplements of protein and fat.
Number of subjects: 0
Study 33477964 — intervention group
Group type: COMPARATOR
Intervention: Standard human milk fortification (historical cohorts).
Number of subjects: 0
Study 33477979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (monoclonal antibody targeting PD1), administered for ten cycles
Number of subjects: 1
Study 33478466 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry data and standardized questionnaires
Number of subjects: 80
Study 33478466 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessments (generic and disease-specific)
Number of subjects: 80
Study 33478466 — intervention group
Group type: EXPERIMENTAL
Intervention: Social determinants of health analysis
Number of subjects: 80
Study 33478469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolstered standard of care and family economic empowerment intervention (incentivized youth financial savings account, financial literacy training, peer mentorship)
Number of subjects: 702
Study 33478469 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 702
Study 33478583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersectoral care management (ICM) delivered by specially trained nurses
Number of subjects: 0
Study 33478583 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative evaluation methods
Number of subjects: 0
Study 33478637 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned PCI after TAVR
Number of subjects: 133
Study 33478637 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable bioprosthesis
Number of subjects: 133
Study 33478637 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable bioprosthesis
Number of subjects: 133
Study 33478646 — intervention group
Group type: EXPERIMENTAL
Intervention: TriClip transcatheter tricuspid valve repair system
Number of subjects: 85
Study 33478647 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter treatment of secondary tricuspid regurgitation
Number of subjects: 0
Study 33478647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33478715 — intervention group
Group type: EXPERIMENTAL
Intervention: His bundle pacing (HBP) with SelectSecure Model 3830 lead
Number of subjects: 69
Study 33478795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Dietary Inflammatory Index (ADII) at diagnosis
Number of subjects: 1478
Study 33478795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Dietary Inflammatory Index (ADII) six months after diagnosis
Number of subjects: 1478
Study 33478921 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib in combination with bendamustine and rituximab
Number of subjects: 10
Study 33478934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemic children
Number of subjects: 200
Study 33478934 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 200
Study 33479501 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient
Number of subjects: 8
Study 33479501 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoVax
Number of subjects: 8
Study 33479511 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity during frustration blocks
Number of subjects: 69
Study 33479511 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity during nonfrustration blocks
Number of subjects: 69
Study 33479856 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine 25 mg BID
Number of subjects: 12
Study 33479856 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine 50 mg BID
Number of subjects: 12
Study 33479856 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine 75 mg BID
Number of subjects: 12
Study 33479856 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine (all doses)
Number of subjects: 12
Study 33480187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fornix deep brain stimulation (fx-DBS)
Number of subjects: 39
Study 33480607 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative physical therapy (10 sessions)
Number of subjects: 63
Study 33480607 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls); N=20
Number of subjects: 63
Study 33480608 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (analgesic)
Number of subjects: 206
Study 33480855 — intervention group
Group type: EXPERIMENTAL
Intervention: Priority for the First Nursing Visit Tool (PREVENT)
Number of subjects: 0
Study 33480854 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Marshmallow Test (DMT) app self-report measures of impulsivity
Number of subjects: 116
Study 33480854 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Marshmallow Test (DMT) app mobile behavioral tasks (Balloon Analogue Risk Task, Go-No-Go task)
Number of subjects: 116
Study 33480854 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT app assessing impulsivity in daily life
Number of subjects: 116
Study 33480862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy (RRSO) before 45 years of age
Number of subjects: 750
Study 33480862 — intervention group
Group type: COMPARATOR
Intervention: Control group (women who did not undergo RRSO or underwent RRSO after 55 years of age)
Number of subjects: 750
Study 33481011 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline A1c
Number of subjects: 942
Study 33481011 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up A1c
Number of subjects: 942
Study 33481150 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Boys into Men (CBIM) program
Number of subjects: 2493
Study 33481332 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed light exercise (30 minutes of daily light exercise)
Number of subjects: 367
Study 33481332 — intervention group
Group type: COMPARATOR
Intervention: Standard mTBI instructions (gradual return to exercise following symptom resolution)
Number of subjects: 367
Study 33481332 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed light exercise
Number of subjects: 367
Study 33481332 — intervention group
Group type: COMPARATOR
Intervention: Standard mTBI instructions
Number of subjects: 367
Study 33481403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative methadone (0.1 mg/kg, maximum 5 mg) and postoperative every 12 hours for 3-5 doses
Number of subjects: 38
Study 33481418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances (including sleep duration, sleep timing, and sleep disordered breathing)
Number of subjects: 0
Study 33481552 — intervention group
Group type: EXPERIMENTAL
Intervention: ITx alone
Number of subjects: 35
Study 33481552 — intervention group
Group type: EXPERIMENTAL
Intervention: ITx plus bone marrow-derived hematopoietic stem cells
Number of subjects: 35
Study 33481552 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of immunosuppressive therapy
Number of subjects: 35
Study 33481553 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 13
Study 33481553 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 13
Study 33481553 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased existing baseline immunosuppression
Number of subjects: 13
Study 33481553 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 13
Study 33481553 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified histopathological grading system
Number of subjects: 13
Study 33481557 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) ablation of the globus pallidus internus
Number of subjects: 20
Study 33481672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior oral contraceptive use
Number of subjects: 0
Study 33481672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior oral contraceptive use)
Number of subjects: 0
Study 33481989 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC CAT (Computerized Adaptive Test)
Number of subjects: 406
Study 33481995 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder tissue irritability rating system (STAR-Shoulder)
Number of subjects: 101
Study 33481995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) measures
Number of subjects: 101
Study 33482005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait variability measured as GaitSD
Number of subjects: 16
Study 33482005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire (FOPQ)
Number of subjects: 16
Study 33482005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire (FOPQ) - Avoidance scores
Number of subjects: 16
Study 33482005 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Disability Inventory
Number of subjects: 16
Study 33482005 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test
Number of subjects: 16
Study 33482628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot smoking cessation program
Number of subjects: 319
Study 33482774 — intervention group
Group type: EXPERIMENTAL
Intervention: PConnect parent program co-led by parent peer facilitator and Head Start staff facilitator, 10 sessions
Number of subjects: 10
Study 33483182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 140
Study 33483182 — intervention group
Group type: COMPARATOR
Intervention: External validation cohort
Number of subjects: 140
Study 33483352 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat atrial fibrillation catheter ablation (AFCA) in women
Number of subjects: 443
Study 33483352 — intervention group
Group type: COMPARATOR
Intervention: Repeat atrial fibrillation catheter ablation (AFCA) in men
Number of subjects: 443
Study 33483617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat plus azacitidine
Number of subjects: 0
Study 33483617 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (control)
Number of subjects: 0
Study 33483802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion (0.15 mg/kg/h titrated toward 0.6 mg/kg/h)
Number of subjects: 23
Study 33483802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion
Number of subjects: 23
Study 33483920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac autonomic modulation (CAM) in overweight and physically active adults
Number of subjects: 256
Study 33483920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac autonomic modulation (CAM) in normal weight groups
Number of subjects: 256
Study 33483920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended levels of physical activity
Number of subjects: 256
Study 33484136 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lutein and zeaxanthin intake during pregnancy (mean daily intake: 2.6 mg)
Number of subjects: 1580
Study 33484559 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postsurgical hypoparathyroidism
Number of subjects: 20
Study 33484559 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 20
Study 33484567 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital fibroblasts from GO patients
Number of subjects: 12
Study 33484567 — intervention group
Group type: COMPARATOR
Intervention: Control fibroblasts
Number of subjects: 12
Study 33484567 — intervention group
Group type: EXPERIMENTAL
Intervention: GO fibroblasts
Number of subjects: 12
Study 33484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal strain analysis in stroke patients
Number of subjects: 30
Study 33484598 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal strain analysis in healthy controls
Number of subjects: 30
Study 33484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal S', MAD, global longitudinal strain rate, dynamic volumetry-derived parameters
Number of subjects: 30
Study 33484819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry (pre-lunch)
Number of subjects: 15
Study 33484819 — intervention group
Group type: COMPARATOR
Intervention: Satiated (post-lunch)
Number of subjects: 15
Study 33485079 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative capecitabine, oxaliplatin and trastuzumab (XELOX-T)
Number of subjects: 36
Study 33485301 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV 400 mg combined with tenofovir (TDF) and lamivudine (3TC) for 48 weeks
Number of subjects: 20
Study 33485345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless titanium-coated, isoelastic monoblock cup with vitamin E-blended highly cross-linked polyethylene (HXLPE)
Number of subjects: 101
Study 33485461 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for gastric cancer in low-income or lower-middle-income countries
Number of subjects: 15958
Study 33485461 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer in low-income or lower-middle-income countries
Number of subjects: 15958
Study 33485461 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer in upper-middle-income countries
Number of subjects: 15958
Study 33485461 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with major complications in low-income or lower-middle-income countries
Number of subjects: 15958
Study 33485461 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with major complications in upper-middle-income countries
Number of subjects: 15958
Study 33485708 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized food-based nutrition intervention program (6 months duration, caloric restriction of 500-1000 kcal/d when applicable, protein intake of 1.2-1.5 g/kgBW/d, 5-9 servings/day of fruits and vegetables)
Number of subjects: 22
Study 33485708 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized food-based nutrition intervention program
Number of subjects: 22
Study 33485799 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiglucerase treatment
Number of subjects: 475
Study 33486083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications for weight loss
Number of subjects: 0
Study 33486223 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily egg intake
Number of subjects: 48
Study 33486223 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of eggs
Number of subjects: 48
Study 33486874 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN
Number of subjects: 420
Study 33486874 — intervention group
Group type: COMPARATOR
Intervention: NUC-IFN
Number of subjects: 420
Study 33486971 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasound therapy
Number of subjects: 0
Study 33486971 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33486983 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural tachycardia syndrome (PoTS)
Number of subjects: 19
Study 33486983 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 33487029 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line antiretroviral (ART) treatment
Number of subjects: 500
Study 33487029 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (QoL) assessment at week 4
Number of subjects: 500
Study 33487029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for self-reported adherence at week 4, VL and CD4 at baseline, cognitive functioning, pain and mental health domains
Number of subjects: 500
Study 33487029 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis of QoL and adherence
Number of subjects: 500
Study 33487127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)D); specific dosage and duration not mentioned
Number of subjects: 0
Study 33487129 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 31
Study 33487279 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin treatment for 78 weeks
Number of subjects: 78
Study 33487289 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative-quantitative food plan for 6 months
Number of subjects: 6
Study 33487299 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day fasting (ADF) with a low carbohydrate diet (600 kcal 'fast day' alternated with an ad libitum 'feast day')
Number of subjects: 31
Study 33487299 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day fasting (ADF) with a low carbohydrate diet
Number of subjects: 31
Study 33487468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg CV7202
Number of subjects: 55
Study 33487468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg CV7202
Number of subjects: 55
Study 33487468 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg CV7202
Number of subjects: 55
Study 33487468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg CV7202 (after two doses)
Number of subjects: 55
Study 33487468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg CV7202 (after two doses)
Number of subjects: 55
Study 33487468 — intervention group
Group type: COMPARATOR
Intervention: Rabipur (Control)
Number of subjects: 55
Study 33487525 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher isometric muscle strength
Number of subjects: 22
Study 33487525 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance reached in the 6MWT
Number of subjects: 22
Study 33487525 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AT stiffness
Number of subjects: 22
Study 33487525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle power
Number of subjects: 22
Study 33487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 2% (40 ml)
Number of subjects: 50
Study 33487824 — intervention group
Group type: COMPARATOR
Intervention: Articaine 2% mixed with dexmedetomidine (1 μg.kg) (40 ml)
Number of subjects: 50
Study 33488576 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with fimaporfin + light
Number of subjects: 96
Study 33488576 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hiltonol and vaccine antigens only)
Number of subjects: 96
Study 33489806 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment patterns (type/duration, number of lines, completion rate)
Number of subjects: 8800
Study 33489806 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage treatment (starting from 1 December 2010)
Number of subjects: 8800
Study 33489806 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection at baseline (diagnosis) and 6 and 12 months after
Number of subjects: 8800
Study 33489806 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for treatment duration and overall survival
Number of subjects: 8800